MX385673B - Productos terapeuticos de anticuerpos que se enlazan a cd47. - Google Patents
Productos terapeuticos de anticuerpos que se enlazan a cd47.Info
- Publication number
- MX385673B MX385673B MX2017011329A MX2017011329A MX385673B MX 385673 B MX385673 B MX 385673B MX 2017011329 A MX2017011329 A MX 2017011329A MX 2017011329 A MX2017011329 A MX 2017011329A MX 385673 B MX385673 B MX 385673B
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- derivatives
- polypeptides
- methods
- fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128462P | 2015-03-04 | 2015-03-04 | |
| PCT/US2016/020980 WO2016141328A2 (en) | 2015-03-04 | 2016-03-04 | Antibody therapeutics that bind cd47 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017011329A MX2017011329A (es) | 2018-06-06 |
| MX385673B true MX385673B (es) | 2025-03-04 |
Family
ID=56848772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011329A MX385673B (es) | 2015-03-04 | 2016-03-04 | Productos terapeuticos de anticuerpos que se enlazan a cd47. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10035855B2 (enExample) |
| EP (1) | EP3265125A4 (enExample) |
| JP (5) | JP6643350B2 (enExample) |
| KR (2) | KR102625835B1 (enExample) |
| CN (2) | CN114380912B (enExample) |
| AR (1) | AR103868A1 (enExample) |
| AU (2) | AU2016225993B2 (enExample) |
| IL (2) | IL254321B (enExample) |
| MX (1) | MX385673B (enExample) |
| TW (3) | TWI719966B (enExample) |
| WO (1) | WO2016141328A2 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4124343A1 (en) | 2016-10-20 | 2023-02-01 | I-Mab Biopharma US Limited | Novel cd47 monoclonal antibodies and uses thereof |
| WO2018089508A2 (en) | 2016-11-08 | 2018-05-17 | Ablexis, Llc | Anti-cd47 antibodies |
| AU2018213718B2 (en) | 2017-01-26 | 2022-08-25 | Zlip Holding Limited | CD47 antigen binding unit and uses thereof |
| CA3053392A1 (en) * | 2017-02-28 | 2018-09-07 | The Board Of Trustees Of The Leland Stanford Junior University | Antifibrotic activity of cd47 blockade |
| EP3661965A4 (en) | 2017-08-02 | 2022-07-13 | Phanes Therapeutics, Inc. | ANTI-CD47 ANTIBODIES AND USES THEREOF |
| WO2019095358A1 (zh) * | 2017-11-20 | 2019-05-23 | 泰州迈博太科药业有限公司 | 一种靶向cd47与pd-l1的双功能融合蛋白 |
| US11180552B2 (en) | 2017-12-01 | 2021-11-23 | Seagen Inc. | CD47 antibodies and uses thereof for treating cancer |
| CN110577597B (zh) * | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技（成都）有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
| CN112601544A (zh) * | 2018-07-05 | 2021-04-02 | 三钰生物科技股份有限公司 | 人类抗cd47抗体及其用途 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| SG11202104301SA (en) * | 2018-10-31 | 2021-05-28 | I Mab Biopharma Us Ltd | Novel cd47 antibodies and methods of using same |
| JP7454645B2 (ja) | 2019-07-16 | 2024-03-22 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン並びにその作製方法及び使用方法 |
| EP4045083B1 (en) | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| WO2021113596A2 (en) * | 2019-12-05 | 2021-06-10 | Sorrento Therapeutics, Inc. | Compositions and methods comprising an anti-cd47 antibody in combination with a tumor targeting antibody |
| GB201918230D0 (en) | 2019-12-11 | 2020-01-22 | Prec Therapeutics Ltd | Antibodies and their uses |
| CN113004406B (zh) * | 2019-12-20 | 2022-04-26 | 广东菲鹏制药股份有限公司 | 抗cd47抗体及其应用 |
| CN117736207A (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| CA3172449A1 (en) | 2020-03-27 | 2021-09-30 | Erik Hans MANTING | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| CN116133679A (zh) | 2020-06-30 | 2023-05-16 | 门德斯有限公司 | 白血病衍生细胞在卵巢癌疫苗中的用途 |
| WO2022109227A1 (en) * | 2020-11-19 | 2022-05-27 | Icahn School Of Medicine At Mount Sinai | Combined cancer therapy of b7-h3 and cd47 immune checkpoint inhbitior and methods of use |
| KR102757518B1 (ko) * | 2020-12-07 | 2025-01-21 | (주)이노베이션바이오 | Cd47에 특이적인 항체 및 이의 용도 |
| WO2022148383A1 (en) * | 2021-01-05 | 2022-07-14 | National Institute Of Biological Sciences, Beijing | A bispecific antibody targeting gpc3 and cd47 |
| WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| TW202305006A (zh) | 2021-05-07 | 2023-02-01 | 南韓商益免安協公司 | 與ｃｄ４７及ｐｄ—ｌ１特異性結合的雙特異性抗體 |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| EP4365197A4 (en) * | 2021-06-30 | 2025-05-14 | Innobation Bio Co., Ltd. | Humanized antibody specific to CD47 and pharmaceutical composition containing it for the prevention or treatment of CD47-mediated disease |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| KR102438419B1 (ko) * | 2021-12-01 | 2022-09-01 | 메디포스트(주) | Cd47 과발현 중간엽 줄기세포를 포함하는 폐 질환 예방 또는 치료용 조성물 |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| PE20250157A1 (es) | 2022-04-21 | 2025-01-22 | Gilead Sciences Inc | Compuestos de modulacion de kras g12d |
| CN119384415A (zh) | 2022-07-01 | 2025-01-28 | 吉利德科学公司 | Cd73化合物 |
| EP4554628A1 (en) | 2022-07-12 | 2025-05-21 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| KR20250167002A (ko) | 2023-04-11 | 2025-11-28 | 길리애드 사이언시즈, 인코포레이티드 | Kras 조절 화합물 |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025244201A1 (ko) | 2024-05-22 | 2025-11-27 | 주식회사 이뮨온시아 | 항-cd47 항체를 이용한 진행성 또는 전이성 고형암의 치료 방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138496B2 (en) * | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| EP2111869A1 (en) * | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| JP6166177B2 (ja) * | 2010-05-14 | 2017-07-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体 |
| SG10201700160RA (en) * | 2012-02-06 | 2017-03-30 | Inhibrx Lp | Cd47 antibodies and methods of use thereof |
| PT2900694T (pt) * | 2012-09-27 | 2018-11-13 | Merus Nv | Anticorpos de igg biespecíficos como ativadores de células t |
| CN105121467B (zh) * | 2012-12-03 | 2019-07-05 | 诺夫免疫股份有限公司 | 抗cd47抗体及其使用方法 |
| BR112015013431A2 (pt) * | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
| CN105101997B (zh) * | 2013-02-06 | 2018-11-09 | 印希彼有限合伙公司 | 不减少血小板和不减少血红细胞的cd47抗体及其使用方法 |
-
2016
- 2016-03-04 TW TW105106782A patent/TWI719966B/zh active
- 2016-03-04 AR ARP160100592A patent/AR103868A1/es unknown
- 2016-03-04 EP EP16759606.3A patent/EP3265125A4/en active Pending
- 2016-03-04 KR KR1020177028115A patent/KR102625835B1/ko active Active
- 2016-03-04 JP JP2017546200A patent/JP6643350B2/ja active Active
- 2016-03-04 AU AU2016225993A patent/AU2016225993B2/en active Active
- 2016-03-04 KR KR1020247000720A patent/KR102850868B1/ko active Active
- 2016-03-04 TW TW111131339A patent/TWI843184B/zh active
- 2016-03-04 WO PCT/US2016/020980 patent/WO2016141328A2/en not_active Ceased
- 2016-03-04 CN CN202210050901.6A patent/CN114380912B/zh active Active
- 2016-03-04 MX MX2017011329A patent/MX385673B/es unknown
- 2016-03-04 CN CN201680024600.9A patent/CN107921121B/zh active Active
- 2016-03-04 TW TW110105132A patent/TWI778518B/zh active
- 2016-03-04 US US15/061,771 patent/US10035855B2/en active Active
-
2017
- 2017-09-04 IL IL254321A patent/IL254321B/en unknown
-
2019
- 2019-10-10 JP JP2019186564A patent/JP2020023532A/ja not_active Withdrawn
-
2020
- 2020-12-21 AU AU2020294159A patent/AU2020294159B2/en active Active
-
2021
- 2021-01-06 JP JP2021000870A patent/JP7137646B2/ja active Active
- 2021-01-06 JP JP2021000869A patent/JP7105938B2/ja active Active
- 2021-05-27 JP JP2021089081A patent/JP2021121635A/ja not_active Withdrawn
- 2021-11-09 IL IL287958A patent/IL287958B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX385673B (es) | Productos terapeuticos de anticuerpos que se enlazan a cd47. | |
| MX2017011406A (es) | Terapeuticos de anticuerpo que se unen a tim3. | |
| WO2017015560A3 (en) | Antibody therapeutics that bind lag3 | |
| WO2016164669A3 (en) | Antibody therapeutics that bind cd38 | |
| BR112014028785A2 (pt) | proteínas de ligação a antígeno de st2 | |
| PH12017500890A1 (en) | Antibody drug conjugates | |
| BR112018006251A2 (pt) | anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso | |
| EA201891093A1 (ru) | Антитела, специфически связывающие pd-1, и их применение | |
| BR112018071276A2 (pt) | anticorpos anti-il-33, composições, métodos e usos dos mesmos | |
| BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
| BR112018012352A2 (pt) | anticorpos anti-lag3 e fragmentos de ligação ao antígeno | |
| BR112018074456A2 (pt) | anticorpos que se ligam especificamente aos epítopos do zika vírus e usos dos mesmos | |
| BR112017025191A2 (pt) | anticorpos contra ox40 e uso dos mesmos | |
| BR112018012344A2 (pt) | anticorpos que se ligam especificamente a hla-dr e seus usos | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| BR112018068678A2 (pt) | anticorpos anti-mica | |
| BR112016004324A2 (pt) | anticorpos | |
| UA122479C2 (uk) | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) | |
| PH12017500331A1 (en) | Antigen binding proteins that bind cxcr5 | |
| EA201892774A1 (ru) | Антитела | |
| EA201591131A1 (ru) | Днк-конструкции антитела и способ их применения | |
| WO2013192596A3 (en) | Antigen binding proteins that bind ccr2 | |
| WO2016164657A3 (en) | Antibody therapeutics that bind cd123 | |
| EA201890434A1 (ru) | Антитела к cd154 и способы их применения | |
| BR112017001417A2 (pt) | variantes de proteína de ligação ao fator h e métodos para uso das mesmas |